Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from The Epstein–Barr virus and post‐transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1001/archotol.1995.01890090073014
10.1001/archotol.1995.01890090073014 · External reference
10.3109/10428199609093435
10.3109/10428199609093435 · External reference
10.1016/0002-9343(94)90043-4
10.1016/0002-9343(94)90043-4 · External reference
Clinicopathologic features of posttransplant lymphoproliferative disorders.
1997 · External reference
10.3109/10428199709042491
10.3109/10428199709042491 · External reference
Overview of posttransplant B‐cell lymphoproliferative disorders.
1999 · External reference
Molecular pathology of posttransplantation lymphoproliferative disorders.
1997 · External reference
Unresolved reference
1998 · External reference
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders.
10.1182/blood.v85.2.552.552 · 1995 · External reference
10.1002/(sici)1097-0142(19980515)82:10<1978::aid-cncr23>3.0.co;2-p
10.1002/(sici)1097-0142(19980515)82:10<1978::aid-cncr23>3.0.co;2-p · External reference
Unresolved reference
1992 · External reference
10.1136/jcp.50.11.911
10.1136/jcp.50.11.911 · External reference
10.1136/mp.52.6.307
10.1136/mp.52.6.307 · External reference
Epstein–Barr virus associated diseases in humans.
2000 · External reference
10.1056/nejm198910193211604
10.1056/nejm198910193211604 · External reference
10.3109/10428199409051672
10.3109/10428199409051672 · External reference
10.1097/00007890-199408000-00012
10.1097/00007890-199408000-00012 · External reference
The expression of Epstein–Barr virus latent proteins is related to the pathological features of post‐transplant lymphoproliferative disorders.
1995 · External reference
Unresolved reference
1996 · External reference
10.1016/s0952-7915(99)80062-4
10.1016/s0952-7915(99)80062-4 · External reference
10.2741/rowe
10.2741/rowe · External reference
10.1128/mcb.1.9.785
10.1128/mcb.1.9.785 · External reference
Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein–Barr virus‐infected cells.
10.1128/jvi.62.3.902-911.1988 · 1988 · External reference
10.1073/pnas.88.4.1546
10.1073/pnas.88.4.1546 · External reference
10.1016/s0046-8177(97)90074-5
10.1016/s0046-8177(97)90074-5 · External reference
Epstein–Barr virus‐encoded small RNAs (EBERs) do not modulate interferon effects in infected lymphocytes.
10.1128/jvi.66.8.5133-5136.1992 · 1992 · External reference
10.1099/0022-1317-73-12-3169
10.1099/0022-1317-73-12-3169 · External reference
10.1093/nar/21.19.4483
10.1093/nar/21.19.4483 · External reference
10.1006/viro.1999.9689
10.1006/viro.1999.9689 · External reference
10.1016/0092-8674(89)90433-9
10.1016/0092-8674(89)90433-9 · External reference
Interaction of the lymphocyte‐derived Epstein–Barr virus nuclear antigen EBNA‐1 with its DNA‐binding sites.
10.1128/jvi.63.1.101-110.1989 · 1989 · External reference
10.1128/jvi.68.6.4067-4071.1994
10.1128/jvi.68.6.4067-4071.1994 · External reference
Dissection of DNA replication and enhancer activation function of Epstein–Barr virus nuclear antigen 1.
1988 · External reference
A promoter of Epstein–Barr virus that can function during latent infection can be transactivated by EBNA‐1, a viral protein required for viral DNA replication during latent infection.
10.1128/jvi.63.6.2644-2649.1989 · 1989 · External reference
Transcription of the Epstein–Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
10.1128/jvi.70.6.3561-3570.1996 · 1996 · External reference
10.1038/375685a0
10.1038/375685a0 · External reference
10.1073/pnas.71.10.4006
10.1073/pnas.71.10.4006 · External reference
10.1038/340393a0
10.1038/340393a0 · External reference
10.1099/0022-1317-77-11-2807
10.1099/0022-1317-77-11-2807 · External reference
An Epstein–Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator.
10.1128/jvi.65.11.5880-5885.1991 · 1991 · External reference
10.1073/pnas.90.20.9237
10.1073/pnas.90.20.9237 · External reference
10.1073/pnas.91.16.7568
10.1073/pnas.91.16.7568 · External reference
10.1126/science.8016657
10.1126/science.8016657 · External reference
10.1073/pnas.92.8.3259
10.1073/pnas.92.8.3259 · External reference
10.1128/mcb.15.9.4735
10.1128/mcb.15.9.4735 · External reference
The Epstein–Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TBP.
10.1128/jvi.69.1.585-588.1995 · 1995 · External reference
Epstein–Barr virus nuclear protein 2 transactivates a cis‐acting CD23 DNA element.
10.1128/jvi.65.8.4101-4106.1991 · 1991 · External reference
EBNA‐2 upregulation of Epstein–Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
10.1128/jvi.68.9.5375-5383.1994 · 1994 · External reference
Use of second‐site homologous recombination to demonstrate that Epstein–Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro.
10.1128/jvi.66.5.2893-2903.1992 · 1992 · External reference
Epstein–Barr virus nuclear proteins EBNA‐3A and EBNA‐3C are essential for B‐lymphocyte growth transformation.
10.1128/jvi.67.4.2014-2025.1993 · 1993 · External reference
Mapping of the gene coding for Epstein–Barr virus‐determined nuclear antigen EBNA3 and its transient overexpression in a human cell line by using an adenovirus expression vector.
10.1128/jvi.61.10.3340-3344.1987 · 1987 · External reference
10.1073/pnas.85.4.995
10.1073/pnas.85.4.995 · External reference
Epstein–Barr virus nuclear protein 3C modulates transcription through interaction with the sequence‐specific DNA‐binding protein J kappa.
10.1128/jvi.69.5.3108-3116.1995 · 1995 · External reference
The amino‐terminal domains of Epstein–Barr virus nuclear proteins 3A, 3B, and 3C interact with RBP‐J kappa.
10.1128/jvi.70.5.3068-3074.1996 · 1996 · External reference
A conserved domain of the Epstein–Barr virus nuclear antigens 3A and 3C binds to a discrete domain of J kappa.
10.1128/jvi.70.7.4228-4236.1996 · 1996 · External reference
Epstein–Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.
10.1128/jvi.71.11.8552-8562.1997 · 1997 · External reference
Epstein–Barr virus EBNA3A and EBNA3C proteins both repress RBP‐J kappa‐EBNA2‐activated transcription by inhibiting the binding of RBP‐J kappa to DNA.
10.1128/jvi.70.9.5909-5915.1996 · 1996 · External reference
EBNA2 and EBNA3C extensively and mutually exclusively associate with RBP‐J kappa in Epstein–Barr virus‐transformed B lymphocytes.
10.1128/jvi.70.6.4179-4183.1996 · 1996 · External reference
10.1073/pnas.81.14.4378
10.1073/pnas.81.14.4378 · External reference
10.1099/0022-1317-73-6-1547
10.1099/0022-1317-73-6-1547 · External reference
The Epstein–Barr virus nuclear protein encoded by the leader of the EBNA RNAs (EBNA‐LP) is important in B‐lymphocyte transformation.
10.1128/jvi.65.12.6826-6837.1991 · 1991 · External reference
Epstein–Barr virus nuclear protein LP stimulates EBNA‐2 acidic domain‐mediated transcriptional activation.
10.1128/jvi.71.9.6611-6618.1997 · 1997 · External reference
Cell cycle stage‐specific phosphorylation of the Epstein–Barr virus immortalization protein EBNA‐LP.
10.1128/jvi.70.11.7885-7893.1996 · 1996 · External reference
Epstein–Barr virus leader protein enhances EBNA‐2‐mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain.
10.1128/jvi.71.9.6619-6628.1997 · 1997 · External reference
The Epstein–Barr virus‐encoded nuclear antigen EBNA‐5 accumulates in PML‐containing bodies.
10.1128/jvi.70.4.2562-2568.1996 · 1996 · External reference
10.1002/j.1460-2075.1994.tb06634.x
10.1002/j.1460-2075.1994.tb06634.x · External reference
10.1016/0092-8674(85)90256-9
10.1016/0092-8674(85)90256-9 · External reference
The Epstein–Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B.
10.1016/s0021-9258(18)35741-7 · 1992 · External reference
Upregulation of bcl‐2 by the Epstein–Barr virus latent membrane protein LMP1: a B‐cell specific response that is delayed relative to NF‐kB activation and to induction of cell surface markers.
10.1128/jvi.68.9.5602-5612.1994 · 1994 · External reference
10.1016/0092-8674(95)90489-1
10.1016/0092-8674(95)90489-1 · External reference
10.1093/emboj/16.20.6131
10.1093/emboj/16.20.6131 · External reference
10.1006/viro.1997.8901
10.1006/viro.1997.8901 · External reference
10.1073/pnas.94.23.12592
10.1073/pnas.94.23.12592 · External reference
10.1128/mcb.16.12.7098
10.1128/mcb.16.12.7098 · External reference
10.1038/sj.onc.1201694
10.1038/sj.onc.1201694 · External reference
10.1093/emboj/16.21.6478
10.1093/emboj/16.21.6478 · External reference
The Epstein–Barr virus latent membrane protein (LMP) induction of B cell activation antigens and membrane patch formation does not require vimentin.
10.1128/jvi.63.9.4051-4054.1989 · 1989 · External reference
Phenotypes of Epstein–Barr virus LMP1 deletion mutants indicate transmembrane and amino‐terminal cytoplasmic domains necessary for effects in B‐lymphoma cells.
10.1128/jvi.66.7.4612-4616.1992 · 1992 · External reference
Transient expression of the Epstein–Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis.
1992 · External reference
Epstein–Barr virus latent infection membrane protein alters the human B‐lymphocyte phenotype: deletion of the amino terminus abolishes activity.
10.1128/jvi.62.11.4173-4184.1988 · 1988 · External reference
Epstein–Barr virus latent infection membrane and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA 2 and LMP cooperatively induce CD23.
10.1128/jvi.64.5.2309-2318.1990 · 1990 · External reference
10.1002/eji.1830240635
10.1002/eji.1830240635 · External reference
10.1002/j.1460-2075.1988.tb02874.x
10.1002/j.1460-2075.1988.tb02874.x · External reference
An Epstein–Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase.
10.1128/jvi.65.7.3681-3692.1991 · 1991 · External reference
10.1099/0022-1317-80-8-2193
10.1099/0022-1317-80-8-2193 · External reference
Epstein–Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg‐mediated signal transduction.
1994 · External reference
10.1073/pnas.91.2.772
10.1073/pnas.91.2.772 · External reference
10.1016/s1074-7613(95)80040-9
10.1016/s1074-7613(95)80040-9 · External reference
10.1016/s0065-230x(00)79006-3
10.1016/s0065-230x(00)79006-3 · External reference
Identification of Epstein–Barr virus lytic activity in post‐transplantation lymphoproliferative disease.
1996 · External reference
10.1097/00007890-199509000-00013
10.1097/00007890-199509000-00013 · External reference
10.1097/00007890-199408000-00012
10.1097/00007890-199408000-00012 · External reference
Properties of tumors arising in SCID mice injected with PBMC from EBV‐positive donors.
1994 · External reference
Differential Epstein–Barr virus gene expression in B‐cell subsets recovered from lymphomas in SCID mice after transplantation of human peripheral blood lymphocytes.
10.1128/jvi.69.1.150-155.1995 · 1995 · External reference
Interleukin‐6 and Epstein–Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease.
10.1182/blood.v84.11.3956.bloodjournal84113956 · 1994 · External reference
Induction of interleukin‐6 after stimulation of human B‐cell CD21 by Epstein–Barr virus glycoproteins gp350 and gp220.
10.1128/jvi.70.1.570-575.1996 · 1996 · External reference
Epstein–Barr virus induces Fas (CD95) in T cells and Fas ligand in B cells leading to T‐cell apoptosis.
10.1182/blood.v94.10.3439.422k23_3439_3447 · 1999 · External reference
10.1002/ijc.2910430115
10.1002/ijc.2910430115 · External reference
10.1002/ijc.2910480217
10.1002/ijc.2910480217 · External reference
10.1089/vim.1997.10.183
10.1089/vim.1997.10.183 · External reference
Clinical and immunological considerations in Epstein–Barr virus‐associated diseases.
1996 · External reference
10.1034/j.1399-0012.1999.t01-2-130106.x
10.1034/j.1399-0012.1999.t01-2-130106.x · External reference
10.1097/00007890-199502270-00014
10.1097/00007890-199502270-00014 · External reference
Interleukin‐5 is an autocrine growth factor for Epstein–Barr virus‐transformed B lymphocytes.
10.1182/blood.v79.7.1763.1763 · 1992 · External reference
10.1074/jbc.274.23.16085
10.1074/jbc.274.23.16085 · External reference
10.1016/0145-2126(96)00029-x
10.1016/0145-2126(96)00029-x · External reference
10.1034/j.1399-0012.1999.130405.x
10.1034/j.1399-0012.1999.130405.x · External reference
10.1002/ijc.2910570218
10.1002/ijc.2910570218 · External reference
10.1084/jem.174.4.915
10.1084/jem.174.4.915 · External reference
10.1006/bbrc.1998.9693
10.1006/bbrc.1998.9693 · External reference
Interleukin‐12 expression in human lymphomas and nonneoplastic lymphoid disorders.
10.1182/blood.v85.8.2182.bloodjournal8582182 · 1995 · External reference
Identification of cellular target genes of the Epstein–Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF‐beta igh3) and TGF‐beta 1.
10.1128/jvi.69.7.4206-4212.1995 · 1995 · External reference
10.1007/s002810050045
10.1007/s002810050045 · External reference
10.1016/s1359-6101(98)00023-9
10.1016/s1359-6101(98)00023-9 · External reference
10.1056/nejm199805143382003
10.1056/nejm199805143382003 · External reference
10.1007/bf02785841
10.1007/bf02785841 · External reference
Downregulation of TAP1 in B lymphocytes by cellular and Epstein–Barr virus‐encoded interleukin‐10.
10.1182/blood.v90.6.2390 · 1997 · External reference
IL‐10 inhibits human T cell proliferation and IL‐2 production.
10.4049/jimmunol.148.4.1143 · 1992 · External reference
10.1002/(sici)1096-9896(199802)184:2<177::aid-path977>3.0.co;2-c
10.1002/(sici)1096-9896(199802)184:2<177::aid-path977>3.0.co;2-c · External reference
The expression of Epstein–Barr virus latent proteins is related to the pathological features of post‐transplant lymphoproliferative disorders.
1995 · External reference
10.1007/bf02786473
10.1007/bf02786473 · External reference
10.1038/nm0896-906
10.1038/nm0896-906 · External reference
10.1084/jem.185.9.1605
10.1084/jem.185.9.1605 · External reference
10.1084/jem.184.5.1815
10.1084/jem.184.5.1815 · External reference
10.1006/cimm.1999.1514
10.1006/cimm.1999.1514 · External reference
10.1084/jem.191.10.1649
10.1084/jem.191.10.1649 · External reference
10.1084/jem.176.6.1763
10.1084/jem.176.6.1763 · External reference
10.1002/j.1460-2075.1996.tb01098.x
10.1002/j.1460-2075.1996.tb01098.x · External reference
Involvement of IL‐10 in the autonomous growth of EBV‐transformed B cell lines.
10.4049/jimmunol.158.9.4045 · 1997 · External reference
Endogenous IL‐6 and IL‐10 contribute to the differentiation of CD40‐activated human B lymphocytes.
10.4049/jimmunol.154.6.2533 · 1995 · External reference
10.1084/jem.175.3.671
10.1084/jem.175.3.671 · External reference
10.1128/jvi.74.14.6675-6679.2000
10.1128/jvi.74.14.6675-6679.2000 · External reference
10.1007/bf02737887
10.1007/bf02737887 · External reference
10.1016/s0092-8674(00)80571-1
10.1016/s0092-8674(00)80571-1 · External reference
Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression.
1995 · External reference
10.1097/00007890-199805150-00017
10.1097/00007890-199805150-00017 · External reference
10.1097/00007890-199902270-00021
10.1097/00007890-199902270-00021 · External reference
10.1038/17401
10.1038/17401 · External reference
10.1006/cyto.1996.0118
10.1006/cyto.1996.0118 · External reference
10.1097/00041552-199307000-00018
10.1097/00041552-199307000-00018 · External reference
10.1016/0198-8859(96)00136-x
10.1016/0198-8859(96)00136-x · External reference
10.1002/eji.1830210133
10.1002/eji.1830210133 · External reference
10.1097/00007890-199608150-00012
10.1097/00007890-199608150-00012 · External reference
10.1097/00007890-199805150-00017
10.1097/00007890-199805150-00017 · External reference
10.1128/jvi.74.13.5810-5818.2000
10.1128/jvi.74.13.5810-5818.2000 · External reference
